ASCO 2018
ASCO 2018
Advertisement
DocWire News EditorsASCO 2018 | May 3, 2019
Chicago—Of the estimated 40,000 men in the United States with nonmetastatic castration-resistant prostate cancer ...
Read More
DocWire News EditorsASCO 2018 | July 11, 2018
Chicago—Researchers in California conducted a study to compare 10-year treatment outcomes of radical prostatectomy ...
DocWire News EditorsASCO 2018 | May 29, 2018
Chicago—Results from a previous study of patients with metastatic castration-resistant prostate cancer (mCRPC) ...
DocWire News EditorsASCO 2018 | July 11, 2018
Chicago—There is a high risk for the development of metastatic disease and prostate cancer-related mortality in ...
DocWire News EditorsASCO 2018 | May 29, 2018
Chicago—Results from recent studies have demonstrated the high frequency with which metastatic prostate cancer can ...
DocWire News EditorsASCO 2018 | May 29, 2018
Chicago—The current standard of care in patients with very high risk prostate cancer is radiotherapy and 18 to 28 ...
DocWire News EditorsASCO 2018 | May 29, 2018
Chicago—Androgen signaling is not entirely suppressed with androgen deprivation therapy (ADT) with GnRH analogs. ...
DocWire News EditorsASCO 2018 | May 29, 2018
Chicago—There is no evidence that the risk of prostate cancer is increased with testosterone treatment in hypogonadal ...
DocWire News EditorsASCO 2018 | July 11, 2018
Chicago—There are few available data on disease-related complications such a bone fractures and urinary obstruction ...
DocWire News EditorsASCO 2018 | May 29, 2018
Chicago—Results of the TOAD trial demonstrated that in progressive or relapsed prostate cancer patients after radical ...
DocWire News EditorsASCO 2018 | May 29, 2018
Chicago—Sipuleucel-T (sip-T) is an autologous cellular immunotherapy approved in the United States for patients with ...
DocWire News EditorsASCO 2018 | May 29, 2018
Chicago—Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen (PSA) ...
DocWire News EditorsASCO 2018 | May 29, 2018
Chicago—Evaluation of treatment response in patients with metastatic castration-resistant prostate cancer (mCRPC) is ...
DocWire News EditorsASCO 2018 | May 29, 2018
Chicago—Clinical decisions as well as drug development for prostate cancer are facilitated with intermediate clinical ...
DocWire News EditorsASCO 2018 | May 29, 2018
Chicago—During a poster session at the ASCO 2018 Annual Meeting, Paul Sargos, MD, of the Institut Bergonié, Bordeaux, ...
DocWire News EditorsASCO 2018 | May 29, 2018
Chicago—In the SPARTAN trial, men with nonmetastatic castration-resistant prostate cancer (nmCRPC) were treated with ...
Advertisement
Advertisement
Advertisement
Latest News

January 7, 2025